BMAC for Knee OA

Is BMAC Right for Your Knee?

Knee osteoarthritis is one of the most studied indications for BMAC therapy — and the evidence, while generally encouraging, includes both meaningful positive results and important limitations. Understanding both sides honestly is essential before making a treatment decision.

For patients in Walnut Creek and throughout the East Bay and Lamorinda area who are looking to manage knee pain, improve function, and delay or avoid joint replacement surgery, BMAC is a worthwhile option to evaluate — particularly for patients with moderate to advanced degeneration who may not be ideal candidates for PRP alone.

What Is BMAC?

Bone Marrow Aspirate Concentrate (BMAC) is a regenerative treatment derived entirely from your own body. A small sample of bone marrow is drawn from the pelvic bone and processed the same day to concentrate its most therapeutically active components — including mesenchymal stem cells, growth factors, platelets, and signaling proteins.

When injected into the knee joint under ultrasound guidance, these concentrated biological signals may help:

  • Reduce chronic synovial inflammation
  • Support cartilage and soft tissue health
  • Slow the progression of degenerative changes
  • Improve pain and functional capacity

BMAC works through cell signaling and biological modulation — it does not directly regrow cartilage, rebuild the joint, or reverse structural damage. It creates a pro-healing environment that supports the body’s own repair mechanisms.

Because BMAC is derived from your own body, there is no risk of rejection or allergic reaction.

How BMAC Differs From PRP for the Knee

Both PRP and BMAC are autologous orthobiologic treatments derived from your own blood or bone marrow. For the knee, PRP is typically the first-line regenerative option — it is less invasive, involves only a blood draw, and has a larger body of evidence.

BMAC is generally considered when:

  • Degeneration is more advanced and PRP alone may be insufficient
  • Prior PRP treatment provided incomplete or short-lived relief
  • The clinical picture suggests that a higher concentration of regenerative cells and growth factors may be beneficial

BMAC requires bone marrow aspiration from the pelvic bone, which is a more involved procedure than PRP preparation. This is discussed in detail during your consultation.

What the Evidence Shows — The Case For BMAC

The evidence for BMAC in knee osteoarthritis includes some compelling long-term data:

  • A 2024 study in Scientific Reports followed 37 knees with advanced osteoarthritis (Kellgren-Lawrence grades III and IV) over four years, reporting significant improvements in validated pain and function scores, a 95% success rate, and notably — not a single knee replacement was required through four years of follow-up
  • A 2025 comprehensive narrative review found BMAC provides short- to mid-term symptomatic relief and functional improvement compared to hyaluronic acid, PRP, and corticosteroids, with some studies indicating potential to delay total knee arthroplasty
  • A systematic review of randomized controlled trials found 94% of patient-reported outcomes demonstrated significant improvement from baseline following BMAC injection, with pain scores improving meaningfully through 12-month follow-up
  • A 2024 study of 285 knees found significant improvements in pain and function at 7-month follow-up, with a low overall complication rate
  • The American College of Rheumatology (ACR) conditionally recommends orthobiologic treatments including BMAC for appropriate patients with knee osteoarthritis

What the Evidence Shows — The Case for Caution

The picture is not uniformly positive, and patients deserve to know this:

  • BMAC has not consistently demonstrated clear superiority over PRP in direct head-to-head comparisons — for most patients with mild to moderate knee OA, PRP remains the better-supported first-line regenerative option
  • A 2025 expert opinion review concluded that indications for BMAC remain unclear and that additional high-quality randomized controlled trials are strongly required before definitive recommendations can be made
  • Significant variability in BMAC preparation methods, centrifugation protocols, and cell concentration across studies makes direct comparison difficult — not all BMAC is equivalent
  • Longer-term data beyond four years is limited, and sustained efficacy has not been firmly established
  • The procedure is more invasive than PRP, involving bone marrow aspiration from the pelvis under local anesthesia — this carries a small but real procedural risk compared to a simple blood draw

What This Means for Patient Selection

BMAC for knee osteoarthritis is most appropriate when:

  • Osteoarthritis is moderate to advanced (Kellgren-Lawrence grades II–IV)
  • PRP has been tried and provided insufficient or short-lived relief
  • The patient is looking to delay or avoid knee replacement surgery
  • The patient is in generally good health and able to tolerate the bone marrow aspiration procedure
  • Realistic expectations about timeline and magnitude of improvement have been established

BMAC is generally not recommended for:

  • Mild knee osteoarthritis where PRP is a more appropriate and less invasive first option
  • End-stage bone-on-bone arthritis with complete joint space loss or significant structural deformity where surgery is clearly indicated
  • Patients with active infection, malignancy, bleeding disorders, or other contraindications to the procedure

Before Your Procedure

Avoid NSAIDs (such as ibuprofen, Mobic, naproxen, or Celebrex) for at least one week before and one week after your BMAC injection. NSAIDs interfere with the inflammatory signaling that drives the treatment’s effectiveness.

What to Expect

The procedure is performed under local anesthesia and image guidance. Bone marrow is aspirated from the posterior iliac crest of the pelvis, processed on-site, and injected into the knee joint under ultrasound guidance — typically within the same appointment. The full procedure takes approximately one to two hours.

Most patients return to light activity within a few days. Mild soreness at both the aspiration and injection sites is common for several days. Meaningful improvements in pain and function typically develop gradually over four to twelve weeks, with continued gains possible over several months.

From a Research & Clinical Perspective

Evidence supports BMAC for improving pain and function in patients with moderate to advanced knee osteoarthritis, including some patients who may not be ideal PRP candidates. A 2024 four-year follow-up study in advanced knee OA is particularly compelling. However, BMAC has not demonstrated consistent superiority over PRP in direct comparisons, most existing studies involve small sample sizes, and variability in preparation methods limits the strength of conclusions.

Dr. Murakami will review the current evidence alongside her clinical experience to discuss what is most appropriate for your specific condition.

Fees & Payment

BMAC is not covered by insurance and is paid out of pocket. Fees are discussed transparently during your consultation. We accept all major credit and debit cards, FSA cards, and HSA cards. This practice does not accept Medicare, Medi-Cal, or HMO plans.

[Request an Appointment]

Sources & Further Reading

The following peer-reviewed studies informed the content on this page. Links open in a new tab.

Supporting Evidence

Limitations and Negative Evidence

This page was last reviewed March 2026.

BMAC Consultation in Walnut Creek with Dr. Murakami